free survival rates of > 90% at minimum 5-year follow-up have been reported. 3, 6, 7, 19, 20, 23, 33, 41, 42, 48 Comparable rates for those undergoing SRS as primary management have been described. 3, 6, 9, 16, 18, 19, 23, 33, 34, 42, 44, 48 In clinical practice, postradiosurgery meningioma follow-up consists of regular outpatient visits and serial imaging analyses. Commonly, clinicians may describe the imaging response categorically as regressed, enlarged, or stable and, if measured, use simple measurements of tumor diameter. Although this evaluation may suffice for immediate management, qualitative descriptions of response do little to characterize the true nature of tumor response after any form of therapy. Additionally, given the heterogeneous nature of meningiomas and the possibility of distant recurrence or delayed malignant progression, 4, 22 quantitative characterization of volume response may assist clinicians in patient risk assessment and long-term clinical decision making. Few prior studies have attempted to quantitatively characterize the nature of meningioma volume response following SRS, and most have focused on long-term changes in absolute volumes. 1, 7, 48 The objective of this study was to quantitatively assess the early radiobiological response of meningiomas following SRS and to evaluate volumetric properties as predictors of long-term tumor control.
methods study population
The University of Pittsburgh Institutional Review Board approved this study. From our database of more than 12,000 patients undergoing Gamma Knife radiosurgery (GKRS) at the University of Pittsburgh Medical Center Presbyterian Hospital, we performed a retrospective cohort study of patients undergoing GKRS for meningiomas between April 2002 and July 2010. Meningiomas were diagnosed using either imaging criteria alone and managed primarily with GKRS or using histological confirmation following prior resection or biopsy. No patients were excluded based on histological tumor grade. Patients were required to have at least one follow-up image suitable for volumetric analysis in the institutional electronic imaging system (which was initiated in 2002) to be included in this study. Patients with prior resection undergoing immediate SRS to the tumor bed, undergoing repeat SRS, or without available or appropriate images in the local imaging system were excluded. Clinical data were obtained through a review of the patients' electronic medical record, the Gamma Knife database, and available imaging studies. Data collected included patient demographic information, clinical history of neurological symptoms, tumor location, prior treatments, and aspects of the radiosurgical dose plan.
radiosurgery technique
Our radiosurgical technique has been described in detail in previous reports. 20 In brief, radiosurgery was performed under local anesthesia with mild sedation as necessary, using a Leksell Gamma Knife (Elekta Instruments, Inc.). After application of a Leksell model G stereotactic frame, high-resolution, volume acquisition stereotactic MRI studies were obtained. Image-integrated isodose plans were created to enclose the irregular tumor borders.
The dose received by adjacent critical structures was determined and selective beam blocking was used if necessary. The neurosurgeon, radiation oncologist, and medical physicist selected maximal and margin dose. After GKRS, patients were typically discharged on the same day. In general, for WHO Grade I meningiomas, follow-up imaging was planned for 3-6 months after radiosurgery, then at 1-year intervals for the first 2 years, and at intervals of 3-4 years thereafter; earlier imaging may be obtained based on clinical judgment and course.
tumor imaging and volumetric analysis
Images suitable for volumetric analysis included axial T1-weighted, gadolinium-enhanced MRIs. When available, high-resolution spoiled gradient echo sequences were used. Slice thicknesses ranged from 1.5 to 5 mm; however, specific sequences and thicknesses varied due to patient preference for follow-up location. On each image slice, tumor surface area was calculated by delineating a freehand region of interest around the contrast-enhancing lesion via institutional radiology software. Cystic portions of the lesion were excluded. Tumor volume was subsequently calculated as the sum of the surface areas multiplied by the slice thickness 40 ( Fig. 1A) . Volume was calculated on the day of radiosurgery as a baseline, and then on each followup MRI until the last available scan or until the patient underwent resection or repeat SRS. Volumetric statistics calculated at each follow-up time point include the volume percent change (%∆V) from baseline and the volume rate of change, represented as both an absolute rate of change (ARC), in cm 3 /month, and percent rate of change (PRC), in percent/month (Fig. 1B-D) .
The final volume available for each patient was compared with the initial, baseline volume for classification into 1 of 3 outcome groups. Tumors that ultimately progressed were defined as those achieving a volume > 15% above the baseline volume on the final available follow-up image. Tumors that remained stable were defined as those within a range of ± 15% of the baseline volume. Tumors that regressed on the final available image were defined as those achieving a volume > 15% below the baseline volume. For purposes of analysis, images were grouped into 3-month intervals.
statistical analysis
Statistical analyses were performed using STATA (version 12.0, StataCorp). Descriptive statistics were used to describe the patient population and treatment variables. Statistical significance was set at a = 0.05 a priori. The nonparametric Kruskal-Wallis test (for continuous variables) was used to compare volumetric statistics between groups at each 3-month time point. When considering the data as a binomial outcome (progression vs stable or regressed), the nonparametric Wilcoxon rank-sum (for continuous variables) and Fisher exact (for categorical variables) tests were used to correlate demographic and treatment covariates with progression. Multivariable logistic regression was used to analyze volumetric statistics in the first year of follow-up as primary predictors of progression after adjusting for clinical covariates. Regression models were created using covariates that were statisti-cally significant on univariable analysis, and only one volumetric statistic was used per model for the purposes of comparison at different time points. Clinically significant interactions and possible confounding variables were addressed. The final model included one volumetric statistic adjusted for follow-up length, age at treatment, treatment percent isodose, baseline volume, and history of resection.
results
clinical characteristics and treatment parameters in the study population We identified 676 patients who underwent GKRS between 2002 and 2010, and of this cohort 252 patients (37%) were included in this study. The remainder were excluded for lack of appropriate intrainstitutional imaging for volumetric analysis, GKRS to a resection bed, or repeat GKRS. The median age at time of radiosurgery was 56.4 years (range 14.6-87.6 years), 73% were female, and 27% were male. Of 88 patients (35%) with a history of either resection or biopsy, 97% were classified as WHO Grade I. In this group, 2 patients had biopsy results showing pathological features consistent with WHO Grade I meningioma. Of these 2 patients, 1 underwent resection and subsequent GKRS for eventual recurrence. The other underwent GKRS as primary management. Of 87 patients with prior resection, 27 underwent gross-total resection and were treated with GKRS for tumor recurrence. Sixty patients had prior subtotal resection and were treated with GKRS for residual or recurrent tumor. Presenting symptoms included headache (22%), seizure (10%), and focal neurological deficit (33%) such as cranial nerve palsies, focal weakness, or sensory changes. The mean symptom duration prior to GKRS was 2.9 months (SD 5.3 months). Distribution of tumor location is provided in Table 1 . The SRS parameters are summarized in Table 2 . The median target volume was 2.0 cm 3 (range 0.12-25.4 cm 3 ), and the SRS dose to the tumor margin varied from 10 to 18 Gy prescribed to the 40%-70% isodose line. A representative case demonstrating the region of interest and dose planning is described in Fig. 2 .
descriptive volumetric analysis
At the time of SRS, the median baseline tumor volume for the study population was 3.54 cm 3 ) that differed significantly from baseline (p < 0.001) ( Table 3) . Over the course of the first year, the mean %∆V steadily decreased, from an average of -20.5% in the first 3 months post-SRS until a gradual nadir of -38.7% was reached at 33 months (Fig. 3) .
Of the 252 meningiomas irradiated, 168 (67%) ultimately regressed, 67 (26%) remained stable, and 17 (7%) ultimately progressed; tumors in these categories were defined as achieving a volume on the final available followup image of V < 85%, V ≥ 85% but ≤ 115%, or V > 115%, respectively. Baseline volumes were similar in each group (p = 0.482), and final volumes were significantly larger in tumors that progressed (p < 0.001), supporting the use of a ∆V of 15% as a cutoff for progression. Tumors that regressed did so a median of -1.27 cm 3 (range -12.05 to -0.11 cm 3 ) or -36.37% (range -87.63% to -15.52%) over the course of median 24.33-month follow-up (range 2.14-104.61 months). In contrast, those tumors that remained stable regressed a median of -4.35% (range -14.79% to 15.00%), and meningiomas that ultimately progressed displayed an absolute median increase of 2.49 cm 3 (range (17) 20 (8) 106 (42) 4 (2) 12 (5) 37 (15) 14 (6) 17 (7) Symptoms Headache Seizure Neurological deficit 55 (22) 26 (10) 82 ( Table 3 ). Over the course of the first follow-up year post-SRS, there were 55, 141, and 47 observations available for analysis at the 3-, 6-, and 12-month time points. The mean %∆V became significantly different by 3 months, with continued diversion up to 33 months (Table 4 and Fig. 4 ).
volumetric rate of change
Meningiomas that regressed demonstrated a decrease of -18.17% (SD 23.99%), with a maximum rate of -0.57 (SD 0.72) cm 3 /month or -6.39%/month (SD 10.10%/ month) in the first 3 months post-SRS. The regression response stabilized after approximately 6 months (Table 4) . In contrast, meningiomas that progressed showed a mild early response to therapy, with a mean decline of -2.87% (SD 2.87%) at a rate of -0.11 (SD 0.11) cm 3 /month or -0.85%/month (SD 0.85%/month), and then exhibited a mean increase in size of 13.86% (SD 48.28%) by 6 months after treatment. This pattern did not always hold true. Transient enlargement was observed in 15 tumors before eventual response to SRS, and transient regression was observed in 6 tumors prior to treatment failure. Variability in rate of change was highest in the immediate postoperative months, with a trend toward stability in the 6-to 12-month post-SRS period (Fig. 5) .
analysis of tumor progression
The mean time to progression for 17 tumors was 36.74 months (SD 26.91, median 30.33, range 5.30-91.23 months). The 2-and 5-year tumor control rates were 95% (95% CI 94-99) and 85% (95% CI 74-92), respectively (Fig. 6) ; there were 168 (67%), 118 (47%), and 16 (6%) tumors available for analysis at 1, 2, and 5 years of follow-up, respectively. Although approximately one-third of tumors in this group initially displayed some response to therapy, overall growth was observed by 6 months post-SRS. The median patient age was 64 years (range 33-87 years), 76% were female, and 24% were male. A majority of patients (64%) had a history of resection, and 10 of their 11 tumors were WHO Grade I. Following failure of SRS, 5 patients (29%) underwent resection and 6 (35%) underwent repeat SRS (Table 5) .
On univariable analysis, patient and treatment parameters that were predictive of progression included older age 
discussion
Stereotactic radiosurgery is highly efficacious and safe in the management of intracranial meningiomas. Longterm data, including series describing clinical and imaging outcomes more than 10 years from radiosurgery 11, 15, 36, 39, 43, 45, 48 have demonstrated favorable control rates using SRS as both primary and adjuvant care. Response to treatment, however, is often clinically described categorically, as regressed, enlarged, or stable, which crudely characterizes the true nature of the tumor response. To better understand the radiobiological response to radiosurgery we need to accurately measure that response. What may appear to be subtle changes in linear measurements can be less subtle changes in volume. Understanding the early response profile may assist in predicting longer-term outcomes and may provide clues to help improve the overall outcome.
Volumetric changes of neoplasms after radiosurgery provide insight into a specific tumoral response. Prior investigations in small clinical series have evaluated such responses to radiosurgery in meningiomas, schwannomas, pituitary adenomas, gliomas, and brain metastases. 8, 12, 28, 46 Some of these studies are limited to a degree by a simplified methodology for volumetric measurement. Most commonly a geometrical method using the equation for volume of a sphere, XYZ*(p/6), and the maximum tumor diameter in the X, Y, and Z planes is used; 14, 25, 31 however, lesional irregularities may compromise such methods, and error rates as high as 20% have been reported. 30, 47 In contrast, volume measurement performed using the product of tumor surface area and slice thickness has been shown to be more accurate overall. 14, 30 Here we use this more precise volume measurement on serial post-SRS imaging, with the objective of quantitatively assessing the early radiobiological response of meningiomas following SRS, and evaluating the volumetric parameters as predictors of long-term tumor control. Of 252 tumors with median baseline volume of 3.54 cm 3 , 168 (67%) regressed to < 85% of baseline volume, 67 (26%) remained within 15% of baseline volume, and 17 (7%) progressed to > 115% of baseline volume, to a median final volume of 2.62 cm 3 over median follow-up of 19.50 months. If classifying the control rate based on regression and stability, this results in a 94% control rate overall, which is in line with current literature. 3, 6, 7, 9, 16, 18, 19, 23, 33, 34, 42, 44, 48 Tumors that regressed demonstrated a median absolute volume change of -1.27 cm 3 (-36.37%) at final follow-up, with the greatest rate of change in the first 3 months post-SRS. Few studies have specifically addressed volumetric changes in meningiomas following SRS. Allowing for differences in methodology, specifically the use of a 10% change in volume as a definition of regression/progression, Feigl and colleagues identified comparable rates of regression in 2 studies of meningiomas treated with SRS. 7, 8 In the earlier series, a similar overall control rate of 96.4% was noted. Ultimate regression was identified in 82.4% of the cohort, with mean absolute reduction of 2.1 cm 3 , or 46.1%. 7 The second series similarly identified regression in 74.5% of the cohort, with absolute reduction of 2.1 cm 3 , or 42.1%. 8 Regression in both series was identified as early as 3 months post-SRS, which highlights the importance of early volumetric analysis after treatment. Similarly, Park et al. observed that 86.7% of meningiomas that regressed did so in the first 12 months post-SRS, with half of those demonstrating reduction in the first 6 months. 31 Henzel and colleagues observed a significant mean regression of 16.6% in the first 6 months post-SRS and identified a comparable trend in regression, with the most rapid response in the first 6 months. 13 In contrast, Astner et al. did not observe volume reduction until 11 months posttreatment, and they only noted a mean regression of 27%. Of note, however, the cohort was composed mainly of meningiomas treated with fractionated stereotactic radiotherapy and, of 6 tumors treated with radiosurgery, a median volume reduction of 44% was observed. 1 We identified a small percentage of tumors that demonstrated variable response trends post-SRS. Transient enlargement was observed in 9% of tumors that ultimately regressed (6% overall), and transient regression was seen in 35% of those that ultimately progressed (2.4% overall). Whereas partial treatment response prior to progression may conform to an expected response pattern, transient enlargement prior to regression may be puzzling. Interestingly, this response pattern has been noted in prior studies of both meningiomas 8, 18, 29, 31 and other tumor pathological types. 25, 31 This observation can be related to transient tumoral expansion while the tumor center is responding to the targeted injury and the response is mediated via inflammation, with changes that vary with length of time postradiosurgery. 18, 24, 31 The mean time to documented progression for 17 tumors was 37.74 months; however, initial growth above the baseline volume was observed by 6 months post-SRS. Data from prior studies on time to progression vary significantly, with reported means from 82 to 90 months and ranges from 10 to 144 months. 10, 11, 15, 18, 21, 48 Volumetric studies of meningioma response have identified much shorter times to progression, with evidence of growth as early as 4-10 months post-SRS. 8, 31 Much of this discrepancy, however, may be attributable to definitions of progression, tu- mor location and grade, and radiation dose, because many of these studies defined progression categorically, specifically examined meningiomas of the skull base or cavernous sinus, and limited cohorts based on WHO grade or radiation dose. Multiple studies have addressed meningioma outcomes based on location, and have noted that there may be variability between different cranial base locations. 10, 42 Grade II/III meningiomas tend to occur at the cerebral convexity or parasagittal location, and exhibit poorer treatment response and clinical outcomes in longterm follow-up. 2, 20, 32, 35 Our series included a high percentage of meningiomas that had been diagnosed on neuroimaging and a high percentage of basal and cavernous sinus tumors which, taken together, suggest a high percentage of WHO Grade I meningiomas and contribute to the favorable outcomes in our series; nonetheless, identification of progression at 40 months is significantly less than the means of 80-90 months reported in the literature. This may indicate a higher sensitivity for detection of progression with volumetric analysis.
We identified older age and larger initial tumor volume as consistently significant predictors of progression on multivariable analysis, with longer follow-up, isodose, and history of surgery of variable significance based on the regression model. These findings are consistent with several prior studies; 13, 18, 20, 35, 41, 42 however, many failed to identify pretreatment-or treatment-related factors associated with progression. 1, 6, 9, 31, 34 A unique aspect of our study was the use of volumetric statistics as predictors of tumor progression. We found that initial volume, change in volume, and rate of change could be used to predict progression, most significantly in the 6-to 12-month follow-up range. In Astner et al.'s series of 59 patients, none of whom demonstrated progression over a mean follow-up of 50 months, tumor regression was not time dependent. The authors reported a volume reduction of 17%, 23%, and 30% at < 24, 24-48, and 48-72 months posttreatment, respectively, with a tendency toward increased reduction after a longer time, although no significant trend was identified.
1 In contrast, in their prospective study of 84 meningiomas, Henzel et al. demonstrated similar regression trends to our series, with 16.6%, 24.5%, 27.9%, 33.2%, and 36% tumor reduction at 6, 12, 18, 24, and 36 months, respectively. They found that over the first 3 years post-SRS, tumor volume was reduced continuously toward a steady state, presumably achieved later than 3 years after treatment. We similarly identified a continuous volume reduction in tumors that ultimately regressed. However, we additionally documented the rate 3 /month) in the first postradiosurgical year, separated by outcome group. There is increased variability in rate in the first 3 months (mean -0.46 ± 1.33 cm 3 /month), with stabilization in the rate of change after 6 months. Meningiomas that regressed exhibited a mean change of -18.2% and a maximum rate of change in the first 3 months (mean -0.57 ± 0.72 cm 3 /month or 6.39 ± 10.10%/ month). In contrast, tumors that ultimately progressed exhibited minor initial regression, with a mean of -2.87%, but a slower rate of change (-0.11 cm 3 /month or -0.85%/month). of change and noted that tumors that regressed tended to do so more quickly in the first 6 months, and then continued at a slower and more constant rate afterward. This was in contrast to the mild volume reduction and slower rate of change initially exhibited by those that ultimately progressed.
study limitations
As noted above, tumor location and pathological features may influence the response to radiosurgery. In our cohort the tumors were of mixed location, and many did not have histological confirmation of the diagnosis. The retrospective nature of this study conveys significant bias, with subsequent limitation in interpretation of results, particularly for long-term results. In general, follow-up MRIs are planned at 3-6 months and 1 year post-GKRS; however, the actual timing of initial follow-up MRI in our cohort was extremely variable, ranging from within days of treatment to months later. Part of this may be due to the extremely geographically diverse patient population our center treats, but there are many patient-and diseaserelated factors that may prompt earlier imaging and could confound results. Additionally, follow-up was limited to imaging obtainable in our institution's system to provide a uniform data set, thus resulting in a selection bias for patients obtaining follow-up within our hospital network. The effects of limitations inherent in a retrospective study, particularly irregular scheduling of follow-up imaging and widely varying length of follow-up, are particularly evident in our long-term follow-up results, as evidenced in the Kaplan-Meier curve; a 5-year control rate of 85% is lower than expected based on prior literature and may in large part be attributed to the significant number of censored cases due to limited follow-up.
Technical limitations also exist secondary to retrospective analysis of imaging. Slice thickness and type and/or dose of gadolinium can contribute to variability, and this factor cannot be controlled retrospectively. Studies analyzing the effect of shape and number of slices on accuracy of volume calculation have demonstrated increasing error with irregular or rectangular shape and decreasing number of slices, with errors in the 10%-20% range for irregular or rectangular shapes and 5-10 slices. 47 Furthermore, an increase in the volume of contrast enhancement does not necessarily indicate tumor growth. Instead, it may reflect inflammatory blood-brain barrier changes as part of the cytokine-mediated tumor injury response. This could misclassify progression and reinforces the need for serial imaging.
conclusions
Stereotactic radiosurgery for meningiomas can be used effectively to not only control growth, but also to reduce tumor volume in the first year after treatment. The volume response of meningiomas after SRS is dynamic, and early changes may not be directly indicative of long-term tumor response. Our results suggest that meningiomas that ultimately regress tend to show response in the first 3 months, whereas those that ultimately progress tend do so within 6 months. Quantitative volumetric assessment of tumor response to SRS may help clinicians to better understand early response profiles and provide a valuable tool for patient management following SRS for meningiomas.
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